FDA reviewers advised broad label for Moderna’s next-gen Covid vaccine. Prasad overruled them

Max Bayer

Pharma Reporter

Reviewers at the FDA recommended that Moderna’s next-gen Covid-19 vaccine be approved for all people 12 and older who previously received a shot, defying a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

FDA reviewers advised broad label for Moderna’s next-gen Covid vaccine. Prasad overruled them

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Updated: FDA publishes repository of 200+ drug rejection letters, promising more in the future

FDA hands Capricor a CRL for its Duchenne cell therapy

Sally Susman waves goodbye to Pfizer; Xaira's new president and COO

Century Therapeutics lays off half of its staff, CFO departs as it narrows priorities

Biotech’s Q2 numbers paint a picture of the good, the bad and the ugly

Uncovering the Potential of Targeting the CD38 Pathway for Immune-Mediated Diseases

FDA re­view­ers ad­vised broad la­bel for Mod­er­na’s next-gen Covid vac­cine. Prasad over­ruled them

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Up­dat­ed: FDA pub­lish­es repos­i­to­ry of 200+ drug re­jec­tion let­ters, promis­ing more in the fu­ture

FDA hands Capri­cor a CRL for its Duchenne cell ther­a­py

Sal­ly Sus­man waves good­bye to Pfiz­er; Xaira's new pres­i­dent and COO

Cen­tu­ry Ther­a­peu­tics lays off half of its staff, CFO de­parts as it nar­rows pri­or­i­ties

Biotech’s Q2 num­bers paint a pic­ture of the good, the bad and the ug­ly

Un­cov­er­ing the Po­ten­tial of Tar­get­ing the CD38 Path­way for Im­mune-Me­di­at­ed Dis­eases

FDA reviewers advised broad label for Moderna’s next-gen Covid vaccine. Prasad overruled them

Updated: FDA publishes repository of 200+ drug rejection letters, promising more in the future

FDA hands Capricor a CRL for its Duchenne cell therapy

Sally Susman waves goodbye to Pfizer; Xaira's new president and COO

Century Therapeutics lays off half of its staff, CFO departs as it narrows priorities

Biotech’s Q2 numbers paint a picture of the good, the bad and the ugly

Uncovering the Potential of Targeting the CD38 Pathway for Immune-Mediated Diseases